Updates on Long-Acting Injectable AntipsychoticsAuthor(s): Peter F. Buckley
There have been several recent developments in the area of long-acting injectable antipsychotics. A Phase I study of a four-week long-acting injectable (LAI) formulation of risperidone has been commenced. The study will test the efficacy and tolerability of this four-week LAI formulation in twenty-six patients who have chronic schizophrenia. Risperidone microspheres, administered every two weeks, has been FDA-approved since 2003.